Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20

Blood

Volumn 102, Issue 9, 2003, Pages 3206-3209

  Liu, Ling ^a   Ding, Chunjin ^b   Zeng, Wei ^b   Heuer, Josef G ^b   Tetreault, Jonathan W ^b   Noblitt, Timothy W ^b   Hangoc, Giao ^b   Cooper, Scott ^b   Brune, Kellie A ^b   Sharma, Ganesh ^b   Fox, Niles ^b   Rowlinson, Scott W ^b   Rogers, Danise P ^b   Witcher, Derrick R ^b   Lambooy, Peter K ^b   Wroblewski, Victor J ^b   Miller, James R ^b   Broxmeyer, Hal E ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 20; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BURST FORMING UNIT E; CELL PROLIFERATION; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; CONTROLLED STUDY; CULTURE MEDIUM; ERYTHROID PRECURSOR CELL; GRANULOCYTE PRECURSOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0142152442     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1419     Document Type: Article

References (20)

1. Broxmeyer HE. Myelosuppresive cytokines and peptides. In: Whetton AD, Gordon J, eds. Blood Cell Biochemistryi Hematopoietic Cell Growth Factors and Their Receptors. Vol 7. London, United Kingdom: Plenum; 1996:121-150.
2. Bagby GC Jr. Growth factors, cytokines and the control of hematopoiesis. In: Hoffman R, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, eds. Hematology: Basic Principles and Practices. 3rd ed. New York, NY: Churchill Livingstone; 2000:154-201.
3. Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor Identification, and role in epidermal function. Cell. 2001;104:9-19.
4. Rich BE, Kupper TS. Cytokines: IL-20-a new effector in skin inflammation. Curr Biol. 2001;11: R531-R534.
5. Langle-Rouault F, Patzel V, Benavente A, et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids. J Virol. 1998;72:6181-6185.
6. Broxmeyer HE, Williams DE, Cooper S, et al. Comparative effects in vivo of recombinant murine interleukin 3, natural murine colony-stimulating factor-1, and recombinant murine granulocyte-macrophage colony-stimulating factor on myelopoiesis in mice. J Clin Invest. 1987;79:721-730.
7. Cooper S, Broxmeyer HE. Measurement of interleukin-3 and other hematopoietic growth factors such as GM-CSF, G-CSF, M-CSF, erythropoietin and the potent co-stimulating cytokines, steel factor and Flt-3 ligand. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R, eds. Current Protocols in Immunology. New York, NY: John Wiley & Sons; 1996:6.4.1-6.4.12.
8. Fox N, Solter D. Expression and regulation of the pituitary- and placenta-specific human glycoprotein hormone alpha-subunit gene is restricted to the pituitary in transgenic mice. Mol Cell Biol. 1988;8:5470-5476.
9. Broxmeyer HE, Williams DE, Hangoc G, et al. The opposing actions in vivo on murine myelopoiesis of purified preparations of lactoferrin and the colony stimulating factors. Blood Cells. 1987;13: 31-48.
10. Hangoc G, Yin T, Cooper S, Schendel P, Yang YC, Broxmeyer HE. In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood. 1993;81:965-972.
11. Leary AG, Yang YC, Clark SC, Gasson JC, Golde DW, Ogawa M. Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1987;70: 1343-1348.
12. Sieff CA, Niemeyer CM, Nathan DG, et al. Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3. J Clin Invest. 1987;80:818-823.
13. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, et at. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992;10:1266-1277.
14. Broxmeyer HE, Benninger L, Cooper S, Hague N, Benjamin RS, Vadhan-Raj S. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma. Exp Hematol. 1995;23: 335-340.
15. Kaushansky K. Thrombopoietin: more than a lineage-specific megakaryocyte growth factor. Stem Cells. 1997;15(suppl 1):97-102; discussion 102-103.
16. Kaushansky K, Broudy VC, Sitnicka E, Lofton-Day C, Grossmann A, Sprugel K. Do the preclinical effects of thrombopoietin correlate with its in vitro properties? Stem Cells. 1996;14(suppl 1):108-111.
17. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives nse to all myeloid lineages. Nature. 2000;404: 193-197.
18. McDonald TP, Sullivan PS. Megakaryocytic and erythrocytic cell lines share a common precursor cell. Exp Hematol. 1993;21:1316-1320.
19. Vannucchi AM, Paoletti F, Linari S, et al. Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood. 2000;95:2559-2568.
20. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167: 3545-3549.